Phase 2 clinical trial with temelimab in Post-COVID neuropsychiatric syndromes (GNC-501):
o Recruitment completed in November 2023;
o Preliminary results expected by the end of June 2024.
Cash position of 2.8 million euros as of December 31, 2023, including the pre-financing of 1 million euros of the Research Tax Credit received in January 2024
Financial visibility until the third quarter of 2024 including the capital increase of 5 million euros carried out in Q1 2024
Geneva, Switzerland, April 30, 2024 – 6:30 p.m. CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (PASC, post-COVID or long COVID), today announces its annual results for the financial year ending December 31, 2023 and provides an update on its developments.